Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Corporate Update (Sep 18, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed September 18, 2026
Period End
September 17, 2026
Security
HALO
In the record · 2016–202610-K1110-Q328-K140

HALO filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 140 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed September 18, 2026. Cited figures are marked; the original filing is the authoritative source.

On September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billiona aggregate principal amount of 1.50% convertible senior notes due October 1, 2033.

The offering was increased from the previously announced $1.05 billionb, and the initial purchasers received a 13-day option to buy up to an additional $200 million of notes. The notes are senior, unsecured obligations, and the company expects to close the offering on September 22, 2026. The company expects net proceeds of approximately $1.275 billion, or approximately $1.471 billion if the option is exercised in full.

The initial conversion rate is 7.1509 shares per $1,000c principal amount, equal to an initial conversion price of approximately $139.84 per share, a conversion premium of approximately 27.5% above the $109.68 closing price on September 17, 2026. The company will settle conversions in cash and, if applicable, shares, at its election. The company plans to use approximately $162.5 million of the net proceeds to fund capped call transactions, with an initial cap price of approximately $208.39 per share, a premium of approximately 90.0% above the September 17, 2026 last reported sale price.

Concurrently, the company intends to repurchase $151.7 milliond principal amount of its 0.25% convertible senior notes due 2027 for a total cost of approximately $217.0 million, including accrued interest, and $220.0 million principal amount of its 1.00% convertible senior notes due 2028 for a total cost of approximately $435.5 million, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases or repayment. The filing notes that the note repurchases and related hedging activity by counterparties and holders could affect the market price of the common stock and the notes.

Key Highlights

  1. Priced $1.3 billion of 1.50% convertible senior notes due October 1, 2033, upsized from $1.05 billion, with a 13-day option for up to an additional $200 million
  2. Initial conversion price of approximately $139.84 per share, a premium of approximately 27.5% over the $109.68 closing price on September 17, 2026
  3. Expected net proceeds of approximately $1.275 billion ($1.471 billion if the option is exercised in full); closing expected September 22, 2026
  4. Approximately $162.5 million of proceeds to fund capped call transactions with an initial cap price of approximately $208.39 per share, a premium of approximately 90.0%
  5. Concurrent repurchase of $151.7 million of 2027 Notes (total cost approximately $217.0 million) and $220.0 million of 2028 Notes (total cost approximately $435.5 million)
  6. Notes are senior, unsecured, and offered only to qualified institutional buyers under Rule 144A; conversions may be settled in cash and/or shares at the company's election
  7. Holders may require repurchase at 100% of principal plus accrued interest upon a fundamental change

Frequently Asked Questions

  1. How much capital is Halozyme raising and what are the key terms?

    Halozyme priced $1.3 billion of 1.50% convertible senior notes due October 1, 2033, with interest paid semi-annually. The notes are senior, unsecured obligations, and the initial purchasers have a 13-day option to buy up to an additional $200 million.

  2. At what price would the notes convert into common stock?

    The initial conversion rate is 7.1509 shares per $1,000 principal amount, equal to an initial conversion price of approximately $139.84 per share. This represents a premium of approximately 27.5% above the $109.68 closing price on September 17, 2026. The conversion rate is subject to adjustment in certain events.

  3. What will the company do with the proceeds?

    The company expects net proceeds of approximately $1.275 billion. About $162.5 million will fund capped call transactions, and about $217.0 million and $435.5 million (including accrued interest) will fund repurchases of the 2027 Notes and 2028 Notes, respectively. The remainder is intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases or repayment.

  4. What are capped call transactions and how do they affect dilution?

    The capped call transactions are generally expected to reduce potential dilution upon conversion and/or offset cash payments above principal, for market prices between the conversion price and the cap price. The initial cap price is approximately $208.39 per share, a premium of approximately 90.0% above the September 17, 2026 last reported sale price. Above the cap price, dilution and cash payments would not be offset to the extent the market price exceeds the cap.

  5. When is the offering expected to close and who can buy the notes?

    The company expects to close the offering on September 22, 2026, subject to customary closing conditions. The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers under Rule 144A, and have not been registered under the Securities Act.